Navigation Links
Cephalon Submits Supplemental New Drug Application for FENTORA
Date:11/12/2007

of improper patient selection and/or improper dosing. FENTORA is contraindicated in the management of acute or postoperative pain including headache/migraine. Life-threatening respiratory depression could occur at any dose in patients not regularly taking around-the-clock opioids. The label for FENTORA is currently being updated to reflect these and other important safety considerations. PHYSICIANS AND OTHER HEALTHCARE PROVIDERS MUST BECOME FAMILIAR WITH THE

IMPORTANT WARNINGS IN THIS LABEL.

FENTORA contains fentanyl, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. FENTORA can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing FENTORA in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion. Schedule II opioid substances which include morphine, oxycodone, hydromorphone, oxymorphone, and methadone have the highest potential for abuse and risk of fatal overdose due to respiratory depression.

FENTORA is indicated only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking at least 60 mg of oral morphine/day, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. Because life-threatening respiratory depression could occur at any dose in opioid non-tolerant patients, FENTORA is contraindicated in the management of acute or postoperative pain. This product is not indicated for use in opioid nontolerant patients.

Patients and their caregivers must be instructed that FENTORA contains a medicine in an amount which can b
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
9. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
10. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
11. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)...  StemProtein LLC, a leading manufacturer of stem ... Cell Technologies Inc., announced today that it appoints ... StemProtein. Silberg will help advance the Company,s patented ... Factors (SCFs), a significant consumer opportunity. ... biopharmaceutical industries with substantial executive level experience with ...
(Date:9/3/2015)... ... 2015 , ... If you plan to attend the 27th annual Tradeline ... want to sign up for the tour of Framingham State University's newest addition to ... through of the (8) chemistry teaching labs that are exclusively utilizing (49) filtered ...
(Date:9/2/2015)... , Sep. 02, 2015 ... has announced the addition of Jain PharmaBiotech,s new ... Companies" to their offering. This ... development of sequencing technologies, and their applications. Current ... as companies developing them. Various applications of sequencing ...
(Date:9/2/2015)... , Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report "Gene ... offering. The markets for gene therapy are ... gene therapy product and it is marketed in ... are estimated for the years 2014-2024. The estimates are ...
Breaking Biology Technology:StemProtein Names Thomas H. Silberg As CEO, To Focus On Stem Cell Secreted Proteins Addresing A Variety Of Health And Beauty Related Needs 2StemProtein Names Thomas H. Silberg As CEO, To Focus On Stem Cell Secreted Proteins Addresing A Variety Of Health And Beauty Related Needs 3Erlab Invites You to Tour the Largest Installation of Filtered Fume Hoods in the World 2Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2
... ANDS ) announced today that it will present at ... 3, 2008 at 9:30 a.m. EST (6:30 a.m. PST) at the ... Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will ... ANA598 and ANA773 in hepatitis C and ANA773 in cancer. , ...
... Nov. 25 Sangamo BioSciences,Inc. (Nasdaq: SGMO ... will provide an update on the progress of Sangamo,s ... business strategy at,4:30 pm (ET) on Tuesday, December 2, ... in New York. The company will also update ...
... that Scott Jackson, chief executive officer, is scheduled to present ... New York and the 2008 Mid-Atlantic Capital Conference in Philadelphia. ... update on the company,s clinical development programs. The presentations ... Piper Jaffray Health Care ...
Cached Biology Technology:Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference 2Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference 2Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference 2
(Date:8/20/2015)... The wearable technology market has traditionally ... healthy. However, wearable technology has the potential to ... improve diagnostic capabilities and therapeutic outcomes. Today, Leaf ... Technologies Conference 2015 , where Barrett Larson ... healthcare.    "Over the past decade, ...
(Date:8/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... Alliance and the EMV Migration Forum.  ... Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. direct ... promoting adoption of smart card technology. To ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas ... key contributor to the Submission Content Management ... IRISS, a non-profit forum. Dedicated to the Implementation ... a neutral platform for industry, vendors, health ... information and work towards a standard method ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... -- A new study by Georgetown University Medical Center researchers ... to stop cancer cell growth. The findings, published online ... which is mutated in a majority of families who have ... I. Yarden, PhD, assistant professor in the Department of Human ...
... A new model of the how the protein coat ... access journal BMC Biophysics , shows that ... capsid production (hierarchical assembly) can be more efficient than ... capsid enveloping a virus is essential for protection and ...
... genomic data into meaningful information about the cell is ... human biology and medicine. Researchers at the University of ... proposed a new method that creates a computational model ... protein interactions, discovering how genes and proteins connect to ...
Cached Biology News:Study uncovers mechanism used by BRCA1 to suppress tumors 2Do-it-yourself viruses: How viruses self assemble 2Toward a new model of the cell 2Toward a new model of the cell 3
The Programmable MP-5000P-F Power Supply can be applied for any Microfluidic application....
Rab GDP dissociation inhibitor beta...
... POWER 500V Programmable Power Supply are ... can handle virtually any application from ... blotting. It is unique in offering ... MAX POWER Programmable Power Supply is ...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
Biology Products: